Xgeva 120 mg Injection – Composition, Uses and Medicine Enquiries
Product Overview
Xgeva 120 mg Injection contains Denosumab, a monoclonal antibody that blocks RANK ligand, a signal involved in bone breakdown.
It is used in selected patients with cancer affecting the bones to help prevent skeletal complications and has other specific approved indications.
Xgeva 120 mg should not be described as a routine arthritis or osteoporosis medicine. A different Denosumab product and dosing regimen are used for common osteoporosis indications.
Treatment requires monitoring of calcium levels and dental health because serious low calcium and jaw-related complications can occur.
It is administered by subcutaneous injection under specialist supervision.
The exact concentration and injection presentation should be confirmed against the actual manufacturer-labelled packaging before publishing this product page.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Denosumab | 120 mg (commonly 120 mg/1.7 mL) |
Product Name: Xgeva 120 mg Injection
Generic Name: Denosumab
Brand Name: Xgeva
Strength: 120 mg
Concentration: Commonly 120 mg/1.7 mL — verify actual presentation.
Please verify the exact concentration, injection volume, formulation and manufacturer details against the original product packaging before publishing this product page or proceeding with an enquiry.
Therapeutic Category and Indication
Xgeva 120 mg Injection belongs to the RANK ligand inhibitor category and is classified as a bone-modifying monoclonal antibody.
Its clinical use relates to the prevention of skeletal-related events in certain cancers and other approved indications.
It is used in selected patients with cancer affecting the bones to help prevent skeletal complications and has other specific approved indications.
Xgeva 120 mg should not be described as a routine arthritis or osteoporosis medicine. A different Denosumab product and dosing regimen are used for common osteoporosis indications.
Treatment decisions depend on diagnosis, patient-specific factors, coexisting conditions, interactions and the applicable approved product information.
The listed indications are a general overview, not a substitute for a prescriber’s assessment. The exact approved uses and restrictions should be checked against the product’s current local prescribing information.
Administration Information
Xgeva 120 mg Injection should be administered by a healthcare professional under the skin according to the approved regimen.
Patients should follow prescribed calcium and vitamin D advice and report dental problems or muscle spasms promptly.
The prescribed schedule, duration, missed-dose instructions and monitoring requirements must be provided by the treating clinician.
Patients should not start, switch or stop prescription therapy on the basis of website information.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: Xgeva 120 mg Injection
- Generic Name: Denosumab
- Brand Name: Xgeva
- Strength: 120 mg
- Therapeutic Category: Anticancer
- Medicine Class: RANK Ligand Inhibitor / Bone-Modifying Monoclonal Antibody
- Indication: Prevention of skeletal-related events in certain cancers; other approved indications.
- Dosage Form: Injection.
- Concentration: Commonly 120 mg/1.7 mL — verify actual presentation.
The dosage form, concentration, injection volume and pack size must be matched to the actual manufacturer-labelled presentation.
Available packaging, batch identification, expiry date and remaining shelf life may vary and should be confirmed by an authorised supplier before any transaction.
No pack quantity, stock position or export eligibility is guaranteed by this listing.
Prescription and Patient Safety
Xgeva 120 mg Injection is a prescription medicine that requires specialist supervision.
Treatment requires monitoring of calcium levels and dental health because serious low calcium and jaw-related complications can occur.
Patients should follow prescribed calcium and vitamin D advice and report dental problems or muscle spasms promptly.
The prescribed treatment schedule and monitoring requirements should be determined by the treating clinician.
The exact precautions, monitoring requirements and possible adverse effects should be checked against the current approved product information.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal receives medicine-related enquiries and may help patients, caregivers and eligible healthcare organisations communicate with independent, appropriately authorised pharmaceutical suppliers or service providers.
Medinglobal does not itself manufacture, dispense, sell or export this medicine.
Availability, prescription requirements, lawful supply routes, supporting documents and any destination-country restrictions must be confirmed by the relevant authorised provider.
Submission of an enquiry is not a commitment or guarantee of supply.
How to Submit an Xgeva 120 mg Injection Enquiry
To help identify the requested product, include the following details when submitting an enquiry:
- Product or brand name: Xgeva 120 mg Injection.
- Generic name: Denosumab.
- Required strength and dosage form.
- Required concentration and injection volume, where specified.
- Required quantity.
- Destination country.
- Whether the request is for an individual patient or a healthcare institution.
- Valid prescription or other supporting documentation, where required.
Medinglobal may refer the enquiry to an appropriately authorised independent partner for verification and response.
Any subsequent transaction is subject to the partner’s own legal, clinical and regulatory checks.
Frequently Asked Questions
What is Xgeva 120 mg Injection used for?
It is associated with the prevention of skeletal-related events in certain cancers and other approved indications. Eligibility and approved indications depend on the specific product label and clinician assessment.
What does Xgeva 120 mg Injection contain?
The supplied product information identifies Denosumab 120 mg, commonly presented as 120 mg/1.7 mL. The precise formulation and presentation should be verified against the original product packaging.
Is Xgeva 120 mg a routine osteoporosis medicine?
No. Xgeva 120 mg should not be described as a routine arthritis or osteoporosis medicine. A different Denosumab product and dosing regimen are used for common osteoporosis indications.
How is Xgeva 120 mg Injection administered?
It is administered by a healthcare professional through subcutaneous injection according to the approved regimen.
Does Xgeva 120 mg require medical supervision?
Yes. It requires specialist supervision, including monitoring of calcium levels and dental health.
Can I use this medicine without medical advice?
No. Prescription medicines and specialist therapies require qualified clinical oversight.
Can international patients enquire through Medinglobal?
Enquiries may be submitted, but lawful coordination and any supply depend on authorised partners and applicable local rules.
Does Medinglobal sell or dispense Xgeva 120 mg directly?
No. Medinglobal receives medicine-related enquiries and may help communicate with independent, appropriately authorised pharmaceutical suppliers or service providers. It does not itself manufacture, dispense, sell or export this medicine.
Reviews
There are no reviews yet.